Exercise in patients with metastatic prostate cancer: A comprehensive review cancertreatmentreviews.com/article/S0305-… Physical activity🏃 and structured exercise have been shown to significantly improve quality of life in #ProstateCancer (PC) patients, particularly by alleviating side effects

Our last paper in Annals of Oncology: BRCA and HRR muts have similar prevalence in low and high volume mHSPC, but greater impact in low volume😯. Doublets with ARPi or docetaxel result in comparable poor outcomes for BRCA pts annalsofoncology.org/article/S0923-…

Biggest RWD: Cabo/nivo 1st line #kidneycancer 🔴 N=333, 17 countries & 53 centers ARON project 🟠 mFU 15.9m, mOS not reached, mPFS 33.7m 🟢 ORR 58%, CR 6% 🟣 Poor prognosis: ECOG, sarcomatoid, brain & bone mets 🔵 ≥ G3 AE 37% (Hypertension & HFS) frontiersin.org/journals/oncol…

Datos de mutaciones BRCA y HRR en #prostatecancer hormonos sensible 🧑‍🤝‍🧑 mut HRR & BRCA similres en alto & bajo volumen 📢 El impacto de BRCA/HRR parece mayor el bajo volumen ⚠️Paciente con alt-BRCA tiene peeores resutaldos con dupletes (ACT+ARSI o ADT + Docetaxel)

Finally, a killer application for Y-90 FAPI theranostics? Near complete metabolic responses in 3 patients with treatment refractory solitary fibrous tumors. Ga-68 FAPI had high SUVs (117, 41, 31) with concordant FDG uptake. jnm.snmjournals.org/content/early/… SNMMI Wonderful work from

Keynote Lecture por clara montagut v que nos ha ayudado a entender el valioso rol de la biopsia líquida en cáncer colorrectal. Gracias a la Asociación Colombiana de Hematología y Oncología por esta excelente edición del simposio de Oncología Gastrointestinal. #ACHOGI2025 #TodosSomosACHO

Maite Bourlon ARON project Yüksel Ürün Paola Valdez Enrique Grande Tres Uramigas Francesco Massari Ray Manneh Kopp INCMNSZ_Uronco Sofía Méndez Matteo Santoni We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/blog/maite-bou…

mFOLFIRINOX or S-IROX vs Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611) 💥mFOLFIRINOX or S-IROX was not found to be superior to gem+ nab-pac; in fact, gem+nab-paclitaxel showed numerically better outcomes ascopubs.org/doi/10.1200/JC…

Proud to be part of this great initiative! >300 non clear cell renal cell carcinoma patients analyzed!! sciencedirect.com/science/articl…

Germline variants with therapeutic implications in prostate cancer. It has been a pleasure to work with Masoud Bitaraf and Nima Sharifi in this review focused on the role of HSD3B1 and BRCA2👇sciencedirect.com/science/articl…

🚨 When EV/pembro is not an option, what's the best first-line strategy for cisplatin-ineligible patients with advanced urothelial carcinoma? 🧪 The SOGUG-AUREA study evaluated split-dose cisplatin + atezolizumab in this setting 📄 doi.org/10.1200/OA-25-…

Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial thelancet.com/journals/lance…

🚨 FDA grants accelerated approval to oral zongertinib for advanced HER2 TKD-mutant NSCLC. 📊 ORR: 75%, 58% with responses ≥6 months 💊 More manageable side effects vs. traditional HER2-targeted ADCs Details: drozdogan.com/a-new-era-in-h… #LungCancer #FDA #Oncology

🌟Join us on Sept 19 for the Cleveland Genitourinary Oncology Consortium Symposium, co-hosted by University Hospitals & Cleveland Clinic . Help advance #GUOnc research. RSVP by Sept 5: form.jotform.com/251826610736155 Shilpa Gupta Case Comp Cancer Ctr Jason Brown Moshe Ornstein MD JAGarciaMD

⚡️ First-ever perioperative systemic therapy to beat surgery alone in MIBC. Pembrolizumab (Keytruda) + Enfortumab vedotin (Padcev) significantly improved event‑free survival, overall survival and pathologic complete response in cisplatin‑ineligible patients. #BladderCancer

Out our first translational research from ARON-1α mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations. Matteo Santoni ARON project

In the future we won’t rely on pathology at surgery +/- luck to select patients for adjuvant treatment across cancers. Instead, the identification of residual disease by ctDNA/other biomarkers will be used. These data are a step towards that goal IMO. natera.com/company/news/i…

How exciting #ESMO25 looks like in thge perioperative management of #bladdercancer 🥰🥰🥰 ESMO - Eur. Oncology #IMvigor011 #EV303 ... and more to come!!!!!

IMvigor011 𝗰𝘁𝗗𝗡𝗔+ → 𝗢𝗦/𝗣𝗙𝗦 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 𝘄𝗶𝘁𝗵 𝗮𝘁𝗲𝘇𝗼 𝗰𝘁𝗗𝗡𝗔– → 𝘀𝗽𝗮𝗿𝗲𝗱 𝘂𝗻𝗻𝗲𝗰𝗲𝘀𝘀𝗮𝗿𝘆 𝗜𝗢 Primum non nocere: treating only those with molecular evidence of disease. This is Huge! Congrats to Tom Powles and everyone involved 👏

#SCU25 Ricardo Rendon discussed BCR prostate cancer: 🧬 Highly heterogeneous, 20–40% recur post-curative treatment 📈 PSA-DT <1 yr = strongest predictor of progression 🧪 PSMA PET improves detection but limited for nodal disease 💡 Early sRT <0.5 ng/mL + ADT = best outcomes 🧠